Ansbert Gadicke

Ansbert Gadicke, M.D., co-founded MPM in 1997 with his partner Luke Evnin. Over many years the MPM team they have led has been the inspiration and driving force behind building leading biopharmaceutical companies such as Biomarin (BMRN), CoStim Pharmaceuticals (acquired by Novartis:NVS), Epizyme (EPZM), Pacira (PCRX), Pharmasset (acquired by Gilead:GILD) and Radius (RDUS). MPM believes that these companies are some of the biggest successes in biotech history-companies that ultimately resulted in helping thousands of patients live longer and with vastly improved lives. Ansbert was the lead investor and has served on the boards of several of MPM’s most successful investments including BioMarin, Idenix, Pharmasset and Radius. Prior to the launching of MPM’s venture investing activities, Ansbert led MPM’s Advisory and Investment Banking business, and prior to that he was at The Boston Consulting Group in their Boston office in the Health Care Group. Ansbert was first to study expression of HPV proteins 16 and 18 in human cancer cells and to characterize their cDNAs (which were then used by Pharma for vaccine developments) while under the leadership of Professor Harald zur Hausen, who received the Nobel Prize in Physiology or Medicine in 2008. Ansbert’s commitment to drug discovery and curing disease inspires his work and that of his team in building leading biotechnology companies at MPM, as well as his commitments outside of MPM. He is a member of the Board of Fellows of Harvard Medical School and the Research Advisory Council of Massachusetts General Hospital. Ansbert received an M.D. from J.W. Goethe University in Frankfurt. He held research positions in biochemistry and molecular biology at the Whitehead Institute at MIT and the Biochemistry Department at Harvard University, and has published in leading scientific journals such as Nature and Cell.